vandetanib

FDA Drug Profile

vandetanib is listed in the FDA National Drug Code directory with 3 NDC codes. Available dosage form: powder.

Drug details

Generic Name
vandetanib
Sponsor
Lonza AG
NDC Codes
3
Dosage Forms
POWDER
Active Ingredients
VANDETANIB

Indications and Usage

1 INDICATIONS AND USAGE CAPRELSA is indicated for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease. Use CAPRELSA in patients with indolent, asymptomatic or slowly progressing disease only after careful consideration of the treatment related risks of CAPRELSA. CAPRELSA is a kinase inhibitor indicated for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease. ( 1 ) Use CAPRELSA in patients with indolent, asymptomatic or slowly progressing disease only after careful consideration of the treatment related risks of CAPRELSA. ( 1 )

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.